Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1541-1560 of 2,120 trials

Grass Allergy: Vitamin D Enhanced Immunotherapy

We are studying whether combining intralymphatic immunotherapy with vitamin D helps improve allergy symptoms in people with moderate to severe grass allergies during pollen season.

Allergic Rhinitis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesAllergology

Multiple Myeloma: HDP-101 Treatment Study

We are testing a new treatment called HDP-101 for patients with relapsed or refractory multiple myeloma. The study aims to find a safe dose and evaluate how well it works.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Filgrastim for Severe Bullous Drug Eruptions

We are studying whether Filgrastim can help patients with severe drug reactions like Stevens-Johnson syndrome. The goal is to see if it slows disease progression and improves recovery compared to standard treatment alone.

Stevens Johnson SyndromeLyell Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Tranexamic Acid for Reducing Blood Loss in Cesarean Deliveries with Placenta Previa

We are studying whether a low dose of tranexamic acid can help women with placenta previa experience less blood loss during cesarean delivery. This trial aims to improve safety and outcomes for mothers and their babies.

Placenta PreviaPostpartum Hemorrhage≤3 monthsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsHematology

Multiple Myeloma: New CAR-T Cell Therapy Study

We are testing a new CAR-T cell therapy for adults with relapsed or refractory multiple myeloma who have been treated with lenalidomide. The goal is to see if it works better than standard treatments currently available.

Relapsed/Refractory Multiple Myeloma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Congenital Hyperinsulinism: HM15136 Treatment Study

We are evaluating a new treatment for children with congenital hyperinsulinism to see if it is safe and helps reduce low blood sugar events. This study includes children aged 2 years and older.

Congenital Hyperinsulinism≤3 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyPediatrics

Epithelioid Malignant Pleural Mesothelioma: Atezolizumab and WT1/DC Vaccine

We are studying the safety and effectiveness of adding a new treatment to standard chemotherapy for patients with epithelioid malignant pleural mesothelioma. This trial aims to see if the combination improves treatment outcomes.

Malignant Pleural Mesothelioma6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Ovarian Cancer: Pembrolizumab with Chemotherapy

We are studying a new treatment combining pembrolizumab with chemotherapy for patients with small cell ovarian carcinoma. The goal is to see how well this combination works and to evaluate its safety.

Ovarian Small Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

S-ketamine for Severe Acute Brain Injury

We are studying whether S-ketamine can help patients with severe acute brain injuries who have ongoing brain activity issues. The trial also looks at the safety of this treatment and its effects on recovery over six months.

Brain Hemorrhage and Injury>2 yearsMonitoring phase (IV)Standard MedicinesNeurologyOtolaryngology

Rhizarthrosis: Autologous Stromal Vascular Fraction Injection

We are studying the safety and effects of an injection using your own stem cells for treating rhizarthrosis. This trial will help us understand its impact on pain and joint function over several months.

Rhizarthrosis (Thumb Arthritis)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOrthopedics and TraumatologyRheumatology

CAR-T Cell Therapy: Understanding Extracellular Vesicles

We are studying how extracellular vesicles change before and after CAR-T cell treatment in patients, especially those experiencing neurotoxicity. This research may help improve patient care and treatment outcomes.

CAR T-cell Therapy>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesHematologyInfectious DiseasesOncology

Rectal Cancer: NanoEcho Imaging Study

We are exploring a new imaging method for examining rectal lymph nodes in healthy volunteers and rectal cancer patients. The goal is to assess safety and improve detection of lymph node involvement.

Rectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Pancreatic Cancer: GEMBRAX and FOLFIRINOX Treatment Study

We are exploring a new treatment sequence for patients with locally advanced pancreatic cancer to see if it improves outcomes and tolerability. This study will help us understand its effects on survival and quality of life.

Non-resectable Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Breast Cancer: Trastuzumab-Deruxtecan Treatment Study

We are investigating if switching to a new drug can help patients with HR+ HER2 low metastatic breast cancer who are not responding well to standard therapy. This study aims to find out if this change improves survival and response rates.

Metastatic Breast CancerEfficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyOncology

Lower Risk MDS: Luspatercept and EPO Combination Study

We are studying a new treatment combining luspatercept with EPO for patients with lower risk MDS who haven't responded to previous therapies. The goal is to see if this combination helps improve blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Inflammatory Bowel Disease: Risankizumab-800CW Imaging Study

We are investigating the safety and effectiveness of a new imaging agent for patients with Inflammatory Bowel Disease. This study aims to improve how we visualize drug targeting and inflammation in the intestines.

Inflammatory Bowel Disease (IBD)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyInfectious Diseases

Pneumococcal Vaccine Response in Patients Without a Spleen

We are studying how the timing of pneumococcal vaccination affects immune response in patients who have had their spleen removed. This research may help improve vaccination strategies for asplenic individuals.

Asplenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementAllergologyHematologyInfectious Diseases

DENOCHARCOT Trial: DENOsumab for Charcot Foot in Diabetes

We are studying whether DENOsumab can effectively treat acute Charcot foot in people with diabetes. This trial compares the medication to a placebo to assess its impact on health outcomes.

Diabetic Charcot Foot1-2 yearsMonitoring phase (IV)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Soft Tissue Sarcoma: Doxorubicin Chemotherapy Study

We are investigating whether adding doxorubicin-based chemotherapy helps patients with high-risk localized soft tissue sarcoma live longer without metastasis. This study compares it to standard treatment to assess safety and effectiveness.

Soft Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

CIDP: NVG-2089 Treatment Study

We are evaluating the safety and effectiveness of NVG-2089 for individuals with Chronic Inflammatory Demyelinating Polyneuropathy. This study aims to find out if it can help improve symptoms and overall health.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology